* BioDlink has been named "Emerging CDMO of the Year" for its innovation in complex biologics and...
* BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group fo...
* BioDlink has successfully implemented Veeva QMS, marking a key milestone in its digital transfo...
* Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first appro...
* Celebrating a Shared Milestone: BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG...
* BioDlink helps Lepu Biopharma win China's marketing approval for EGFR-targeted ADC treating rec...
* Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top...
* Bevacizumab Injection officially approved by Indonesia's National Agency of Drug and Food Contr...
- BioDlink's bevacizumab injection secures marketing authorization in Colombia andPakistan followin...
* BioDlink's Bevacizumab Injection has been granted marketing authorization by Nigeria's National ...
* Global Milestone: GMP certification from Argentina, marking a key step in its global expansion ...
* International recognition of quality system with GMP-compliance in the key markets ofBrazil, In...
* BioDlink congratulates Junshi Biosciences on receiving IND approval from China's NMPA for JS212...
SUZHOU,China, Oct. 27, 2022 /PRNewswire/ -- TOT BIOPHARM International Company Limited (TOT BIOPHAR...
SUZHOU, China, June 2, 2022 /PRNewswire/ -- On June 1, 2022, TOT BIOPHARM International Company Lim...
SUZHOU, China, Dec. 2, 2021 /PRNewswire/ -- TOT BIOPHARM International Company Limited (TOT BIOPHAR...
Revenue Surges 78% to RMB23.13 million CDMO Business Achieves Leapfrog Breakthrough Two Products App...